➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
McKesson
Baxter
Johnson and Johnson

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022292

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 022292 describes APTIVUS, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. Additional details are available on the APTIVUS profile page.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.
Summary for 022292
Tradename:APTIVUS
Applicant:Boehringer Ingelheim
Ingredient:tipranavir
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 022292
Mechanism of ActionHIV Protease Inhibitors
Suppliers and Packaging for NDA: 022292
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
APTIVUS tipranavir SOLUTION;ORAL 022292 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0002 0597-0002-01 1 BOTTLE, GLASS in 1 CARTON (0597-0002-01) > 95 mL in 1 BOTTLE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength100MG/ML
Approval Date:Jun 23, 2008TE:RLD:Yes

Expired US Patents for NDA 022292

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Get Started for $10   Get Started for $10
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Merck
AstraZeneca
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.